NEWTOWN, Pa., June 25, 2023 (GLOBE NEWSWIRE) -- The law firm of Edelson Lechtzin LLP is investigating securities fraud and breach of fiduciary duty claims on behalf of shareholders of Churchill Capital Corp II (“Churchill II”) (NYSE: CCX.U), a special purpose acquisition company (“SPAC”), who acquired Churchill II shares before the closing of its business combination with Skillsoft Corp. (“Skillsoft”) (NYSE: SKIL), on or before June 11, 2021.
Skillsoft provides digital learning, training, and talent solutions to assist organizations in democratizing learning. They offer a customized, learner-centric approach to skills development with resources for Leadership Development, Business Skills, Technology and Developer, Digital Transformation, and Compliance. Skillsoft is headquartered in Nashua, New Hampshire. Skillsoft common stock began trading on the NYSE under its new ticker symbol “SKIL,” on June 14, 2021.
Churchill II investors may have claims based on alleged false and misleading statements and/or material omissions contained in the documents used to solicit shareholder approval for the business combination between Churchill II and Skillsoft. Please contact Edelson Lechtzin LLP at 1-844-696-7492 to discuss your investment losses, or by e-mail at elechtzin@edelson-law.com or medelson@edelson-law.com, or you can submit your information online HERE.
For more information, please contact:
Marc H. Edelson, Esq.
Eric Lechtzin, Esq.
EDELSON LECHTZIN LLP
411 S. State Street, Suite N-300
Newtown, PA 18940
Phone: 844-696-7492 or 215-867-2399 ext. 1
Email: elechtzin@edelson-law.com or medelson@edelson-law.com
Web: www.edelson-law.com
About Edelson Lechtzin LLP
Edelson Lechtzin LLP is a national class action law firm with offices in Pennsylvania and California. In addition to cases involving securities and investment fraud, our lawyers focus on class and collective litigation in cases alleging violations of the federal antitrust laws, employee benefit plans under ERISA, wage theft and unpaid overtime, consumer fraud, and dangerous and defective drugs and medical devices.
This press release may be considered Attorney Advertising in some jurisdictions. No class has been certified in this case, so you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. Your ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.
